For virally transduced CAR-T cells, CD4+ CAR-T cells are described to be initially slower in tumor killing than CD8+ CAR-T cells, but are therefore less prone to exhaustion and therefore more persistent in the body after antigen exposure. This evidence concerns the gene CD4 and neoplasm.